Ong MJY, Abd Rahman MSH, Lee VLL, et al. The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders 2025; 18: 1–20. doi:10.1177/17562864251313914

In this article, the text of the following sections has been updated:

1. In the abstract, some data was incorrectly reported in the results section: “There was a statistically significant seizure reduction in the group receiving CBD therapy compared to the placebo group (SMD: −1.50, 95% CI (−3.47, 0.47), p < 0.01).”. The corrected sentence is as follows: “There was a reduction in seizures in the group receiving CBD therapy compared to the placebo group [SMD: –1.50, 95% CI (–3.47, 0.47)], though this did not reach statistical significance.”
2. In the Results, some data were incorrectly reported in the CBD regime and outcomes section as: “Using a random-effects model, as depicted in Figure 4, there is a statistically significant seizure reduction in the group receiving CBD therapy compared to the placebo/control group (mean diffusivity: −1.50, 95% CI (−3.47, 0.47), p < 0.01).”. The corrected sentence is as follows: “Using a random-effects model, as depicted in Figure 4, there was a reduction in seizure frequency in the group receiving CBD therapy compared to the placebo/control group [SMD: –1.50, 95% CI (–3.47, 0.47)], though this did not reach statistical significance.”
3. In the Conclusion section, some data were incorrectly reported as: “Our review has shown that CBD was efficacious as an adjunctive therapy in seizure reduction in adult patients with DRE.”. The corrected sentence is as follows: “Our review has shown that CBD may reduce seizures as an adjunctive therapy in adult patients with DRE, though pooled results did not reach statistical significance.”

The online version of the article has been updated to reflect these corrections.